ATE128730T1 - Prototypische felv-isolate für die verwendung als krankheitsmuster oder impfstoffe. - Google Patents

Prototypische felv-isolate für die verwendung als krankheitsmuster oder impfstoffe.

Info

Publication number
ATE128730T1
ATE128730T1 AT89122964T AT89122964T ATE128730T1 AT E128730 T1 ATE128730 T1 AT E128730T1 AT 89122964 T AT89122964 T AT 89122964T AT 89122964 T AT89122964 T AT 89122964T AT E128730 T1 ATE128730 T1 AT E128730T1
Authority
AT
Austria
Prior art keywords
vaccines
isolates
felv
prototypical
faids
Prior art date
Application number
AT89122964T
Other languages
English (en)
Inventor
Edward A Hoover
James I Mullins
Original Assignee
Univ Harvard
Univ Colorado State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Harvard, Univ Colorado State Res Found filed Critical Univ Harvard
Application granted granted Critical
Publication of ATE128730T1 publication Critical patent/ATE128730T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13061—Methods of inactivation or attenuation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/819—Viral vaccine for feline species, e.g. cats

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT89122964T 1988-12-13 1989-12-12 Prototypische felv-isolate für die verwendung als krankheitsmuster oder impfstoffe. ATE128730T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28413988A 1988-12-13 1988-12-13

Publications (1)

Publication Number Publication Date
ATE128730T1 true ATE128730T1 (de) 1995-10-15

Family

ID=23088994

Family Applications (2)

Application Number Title Priority Date Filing Date
AT89122964T ATE128730T1 (de) 1988-12-13 1989-12-12 Prototypische felv-isolate für die verwendung als krankheitsmuster oder impfstoffe.
AT95100871T ATE221119T1 (de) 1988-12-13 1989-12-12 Prototypische felv-isolate für die verwendung als krankheitsmuster oder impfstoff

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT95100871T ATE221119T1 (de) 1988-12-13 1989-12-12 Prototypische felv-isolate für die verwendung als krankheitsmuster oder impfstoff

Country Status (12)

Country Link
US (1) US6042835A (de)
EP (2) EP0377842B1 (de)
JP (1) JP3164351B2 (de)
AT (2) ATE128730T1 (de)
AU (2) AU4616289A (de)
CA (1) CA2005311C (de)
DE (2) DE68924478T2 (de)
DK (1) DK172633B1 (de)
ES (2) ES2179854T3 (de)
GR (1) GR3018587T3 (de)
IE (1) IE74875B1 (de)
NZ (1) NZ231744A (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8901778D0 (en) * 1989-01-27 1989-03-15 Univ Court Of The University O Manipulatory technique
ZA93216B (en) * 1992-01-17 1993-08-18 Solvay Animal Health Inc Vaccine containing acemannan as an adjuvant.
GB9210337D0 (en) * 1992-05-14 1992-07-01 Univ Court Of The University O Feline leukaemia virus vaccine
US6013517A (en) 1994-05-09 2000-01-11 Chiron Corporation Crossless retroviral vectors
DE69535669T2 (de) 1994-05-09 2008-12-04 Oxford Biomedica (Uk) Ltd. Retrovirale vektoren mit verminderter rekombinationsrate
ES2374526T3 (es) 2003-09-04 2012-02-17 Medarex, Inc. Vector de expresión.
AU2005229411B2 (en) * 2004-03-30 2010-11-18 Centre National De La Recherche Scientifique Polypeptide sequence involved in the modulation of the immunosuppressive effect of viral proteins
RS58289B1 (sr) * 2011-07-20 2019-03-29 Merial Ltd Rekombinantna vakcina protiv virusa mačje leukemije koja sadrži optimizovani gen omotača virusa mačje leukemije
US10988762B2 (en) 2017-02-16 2021-04-27 Bio-Rad Laboratories, Inc. Reverse transcriptases and uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086134A (en) * 1973-09-18 1978-04-25 University Of Glasgow Method for preparation of vaccine against feline leukemia
US4034081A (en) * 1973-09-18 1977-07-05 University Of Glasgow Vaccines against feline leukemia
GB1486186A (en) * 1973-09-18 1977-09-21 Univ Glasgow Vaccines against feline leukaemia and the group of diseases associated with feline leukaemis/virus infection
US4406885A (en) * 1978-12-28 1983-09-27 Research Corporation Preparation of native oncornavirus envelope subunits and vaccines therefrom
US4264587A (en) * 1979-08-01 1981-04-28 Pedersen Niels C Vaccine for preventing persistent feline leukemia viremia in cats
US4434157A (en) * 1979-12-18 1984-02-28 The Ohio State University Research Foundation Method of recovering cell antigen and preparation of feline leukemia vaccine therefrom
US4332793A (en) * 1979-12-18 1982-06-01 The Ohio State University Research Foundation Method of recovering cell antigen and preparation of feline leukemia vaccine therefrom
US4405712A (en) * 1981-07-01 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services LTR-Vectors
US4593002A (en) * 1982-01-11 1986-06-03 Salk Institute Biotechnology/Industrial Associates, Inc. Viruses with recombinant surface proteins
US4701416A (en) * 1983-12-09 1987-10-20 Cetus Corporation Feline leukemia virus vaccine plasmids for fusion protein of the gp70 envelope protein of FELV
EP0156299A3 (de) * 1984-03-26 1987-04-01 Chiron Corporation LTR-modifizierte virale Vakzine
US4663436A (en) * 1984-04-24 1987-05-05 Scripps Clinic And Research Foundation Leukemia-associated virus immunogen, vaccine and assay
US4794168A (en) * 1984-04-24 1988-12-27 Scripps Clinic And Research Foundation Leukemia-associated virus immunogen, vaccine and assay
US4789702A (en) * 1984-05-18 1988-12-06 Cetus Corporation Feline leukemia virus vaccine
US4876089A (en) * 1984-09-06 1989-10-24 Chiron Corporation Feline leukemia virus protein vaccines
US4699785A (en) * 1984-09-18 1987-10-13 The Regents Of The University Of California Cell line producing feline leukemia virus
US4748234A (en) * 1985-06-26 1988-05-31 Cetus Corporation Process for recovering refractile bodies containing heterologous proteins from microbial hosts
AU607399B2 (en) * 1985-09-09 1991-03-07 Cetus Corporation Infectious recombinant virus vaccine for feline leukemia
US4734362A (en) * 1986-02-03 1988-03-29 Cambridge Bioscience Corporation Process for purifying recombinant proteins, and products thereof
AU607427B2 (en) * 1986-05-30 1991-03-07 Cambridge Bioscience Corporation Method of preparation and use for feline leukemia virus antigens
GB2197321B (en) * 1986-09-12 1990-10-03 Genentech Inc Method and vectors for obtaining continuous production of heterologous protein in a eukaryotic host cell line
US5306493A (en) * 1986-10-03 1994-04-26 Miles Inc. FeLV-infected feline cell line
EP0262887A3 (de) * 1986-10-03 1989-07-26 Bayer Corporation FeLV-infizierter Katzenzellstamm
JPH01501939A (ja) * 1987-01-28 1989-07-06 オーソ・フアーマシユーチカル・コーポレーシヨン 免疫抑制ペプチドおよび使用法
AU612404B2 (en) * 1987-09-11 1991-07-11 Genentech Inc. Method for increasing the expression of polypeptides in recombinant cell culture

Also Published As

Publication number Publication date
ES2179854T3 (es) 2003-02-01
AU4616289A (en) 1990-06-21
EP0699758B1 (de) 2002-07-24
DE68929419T2 (de) 2003-04-03
DK172633B1 (da) 1999-03-22
US6042835A (en) 2000-03-28
JP3164351B2 (ja) 2001-05-08
ES2084596T3 (es) 1996-05-16
EP0699758A1 (de) 1996-03-06
DE68924478D1 (de) 1995-11-09
DE68924478T2 (de) 1996-03-07
DE68929419D1 (de) 2002-08-29
EP0377842A1 (de) 1990-07-18
IE960745L (en) 1990-06-13
AU661134B2 (en) 1995-07-13
JPH03117490A (ja) 1991-05-20
NZ231744A (en) 1993-01-27
IE74875B1 (en) 1997-08-13
CA2005311C (en) 2006-05-30
EP0377842B1 (de) 1995-10-04
DK631089A (da) 1990-06-14
AU3710493A (en) 1993-07-15
CA2005311A1 (en) 1990-06-13
DK631089D0 (da) 1989-12-13
IE893974L (en) 1990-06-13
GR3018587T3 (en) 1996-04-30
ATE221119T1 (de) 2002-08-15

Similar Documents

Publication Publication Date Title
ATE47725T1 (de) Zum hervorrufen von aids geeigneter retrovirus vom typ hiv-2, sowie seine antigen- und nukleinsaeure-bestandteile.
Munn et al. Ultrastructural comparison of the retroviruses associated with human and simian acquired immunodeficiency syndromes
DE3750782D1 (de) Zellinie, die virale Aids-Antigene produziert, ohne infektiöse Viruspartikel zu produzieren.
DE3782120D1 (de) Asymmetrische gastrennungsmembranen, deren haut einen dichtegradienten aufweisen.
ES2099066T3 (es) Antigenos a partir de adn sintetico derivado del virus de la inmunodeficiencia humana (hiv-1).
NZ224581A (en) Hiv-2 peptide, aids vaccine
NO863803L (no) Vaksiner og immunoanalyser for ervervet immunsviktsyndrom (aids).
DE3751682D1 (de) Infektiöses System zur Arzneimittelabgabe
GR3017770T3 (en) Feline infectious peritonitis virus diagnostic tools.
ATE334216T1 (de) Impstoff gegen felines immunodefizienz-virus
ES2110411T3 (es) Metodos para cultivar el virus de la hepatitis c (hcv) en lineas celulares de linfocitos b o t.
DE3783282D1 (de) Varianten von lav-viren, deren dns- und proteinkomponenten und deren verwendung, insbesondere zu diagnostischen zwecken und zur herstellung von immunogenen zusammensetzungen.
ATE221119T1 (de) Prototypische felv-isolate für die verwendung als krankheitsmuster oder impfstoff
ES2023928B3 (es) Procedimiento de preparacion de un catalizador, que contiene re, catalizador obtenido y utilizacion de este catalizador para la obtencion de olefinas por metatesis.
ATE91902T1 (de) Hundecoronavirus-impfstoff.
DE3888290D1 (de) Mutanten des infektiösen bovinen Rhinotracheitisvirus, Vakzine die sie enthalten, Verfahren zu ihrer Herstellung und ihrer Verwendung.
DK507079A (da) Svaekket stamme af infektioes katteperitonitisvirus,fremgangsmaade til dens fremstilling og vaccine indeholdende den svaekkedevirusstamme
ATE84018T1 (de) Verfahren zur herstellung von 1,1,-dichlor-1fluoroethan.
DK76688A (da) Vaccine indeholdende f-proteinet fra aids-virus
DK631387A (da) Virusvektor
EP0496787A4 (en) Novel infectious bursal disease virus
FI96864C (fi) Ei-terapeuttisesti käytettävä HIV:n glykoproteiini GP 160 ja menetelmä sen valmistamiseksi
SU700918A1 (ru) Пьезоэлемент контурных колебаний
EP0325998A3 (de) 3,3-Dimethyl-hex-5-en-2-onderivate, Verfahren zu ihrer Herstellung und ihre Verwendung
ATE72220T1 (de) Verfahren zur herstellung von alkylarylaethern.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
EELA Cancelled due to lapse of time